Overview
Plain-language guide
Designed and approved for specific uses that include Chronic idiopathic constipation, IBS-C.
It switches on a receptor in the intestine that increases fluid movement and helps stool pass more easily.
Clinical mechanism
Activates intestinal guanylate cyclase-C in a pH-sensitive manner.
Applications
Human evidence
Multiple human studies and regulatory review support at least one product-specific indication.
Tier 1Preclinical evidence
Mechanistic and preclinical findings are tracked separately and are not treated as proof of human clinical benefit.
Regulatory status
Approved. Regulatory status is product- and jurisdiction-specific and does not automatically follow from an evidence score.
Safety
Well-Characterized Safety
- Adverse effects vary by product and indication
- Contraindications and interactions require label review
Interactions
Review the current product label and indication-specific literature for pharmacologic and absorption interactions.
Treatment pattern
Treatment patterns are product-, indication- and clinician-specific; this educational profile does not provide dosing guidance.
Manufacturing and quality
Approved-product identity, formulation and quality controls must not be extrapolated to compounded or RUO copies.
Sponsor and development history
Bausch Health · Approved. Development programs and ownership can change; confirm current sponsor disclosures.
Sources
- 01Primary regulatory record
Source record prepared for primary-reference linking in the Supabase-backed editorial workflow.
- 02Clinical trial registry
Source record prepared for primary-reference linking in the Supabase-backed editorial workflow.
- 03Peer-reviewed literature
Source record prepared for primary-reference linking in the Supabase-backed editorial workflow.
Gaps and unverified claims
- Evidence must be interpreted by indication and product label.
- Approval does not establish safety or efficacy for off-label or compounded copies.
Last reviewed
August 5, 2026 · Primary-source check needed